95% effective dosage of infusion esketamine in ureteral stent removal

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062077

Enrollment

Unknown

Registered

2022-07-21

Start date

2022-07-23

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ureteral stent removal

Interventions

case series:Drug intervention

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were Society of Anesthesiologists (ASA) physical status I-III patients, the gender not limited,aged between 18-65 years who were scheduled for elective ureteral stent removal in the Second Affiliated Hospital of Chongqing Medical University.

Exclusion criteria

Exclusion criteria: The exclusion criteria included a significant renal or hepatic dysfunction, a known neuromuscular disease, habitual sedative or analgesic use,allergy to any study medications, chronic hypertension without regular treatment, hypoproteinemia and devoid of postoperative telephone access.

Design outcomes

Primary

Measure	Time frame
a valid inhibition of body movement.;	—

Secondary

Measure	Time frame
heart rate,blood pressure,SPO2;Aldrete score;	—

Countries

China

Contacts

Public ContactShu Shiyu

The Second Affiliated Hospital of Chongqing Medical University

514712760@qq.com+86 18917785284

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026